Sem Sælands vei 3
Master i biomatematikk Anna-Simone Josefine Frank ved Farmasøytisk institutt vil forsvare sin avhandling for graden ph.d: Thyroid hormone replacement therapy during pregnancy - Quantifying medication patterns and associated outcomes in the offspring.
PharmaSafe Research Group and DURG Norge is proud to present a guest lecture by Professor Robert Platt, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Canada
Debra Kennedy will give the lecture "MotherSafe – two decades of experience with counseling women and HCP about medication safety in pregnancy and breast feeding".
Ksenia Zagorodnikova will give the lecture "Challenges in use of medications in pregnancy – how do we bridge the gap between research and practice".
Ulrika Nörby will give a lecture on: Fetal effects of maternal drug treatment - risk assessment and communication
Join us on PharmaTox open seminar series.
Attendance is free and open for everybody. Registration is required.
The PharmaSafe group and the PharmaSafe Research Initiative are proud to present a guest lecture by Dr. Jacqueline Cohen, Postdoc at Harvard T.H. Chan School of Public Health.
Lecture by Mollie Wood, Postdoctoral research fellow at the PharmaSafe group and member of the PharmaTOX Strategic Research Initiative, University of Oslo
Seminar organized by the Pharma-Safe group at the School of Pharmacy
By Dr Ross T. Tsuyuki, BSc (Pharm), PharmD, MSc, FCSHP, FACC
Guest lecture by professor Philippe Guérin, University of Oxford, UK.
Guest lecture by Caroline Maltepe, Hospital for Sick Children, Toronto.
The talk will focus on "Nanoparticle interaction with early human placenta", an upcoming topic in reproductive toxicology. Exposure to engineered nanomaterial is steadily increasing, but next to nothing is known about the interaction of nanomaterials with the maternal-embryonic interface in humans. This issue is especially challenging because the kinetics of nanomaterials is considered to be more dependent on the (highly species specific) histologic structure of the placental barrier than the kinetics of low molecular weight substances. This knowledge is important in order to address toxicological concerns but would also facilitate the future development of new therapeutic strategies for a target oriented treatment in pregnancy.